Cutaneous Oncology News

The FDA granted fast track designation to cavrotolimod for two skin cancer indications, according to the agent’s manufacturer.

Disease regression was associated with improved recurrence-free survival and overall survival among certain patients with stage 1 and 2 cutaneous melanomas, according to a study.

Cutaneous oncology news in 2020 included important studies, FDA approvals and research into the causes of melanoma in different populations.

Cutaneous staging was the only significant predictive variable of disease-specific survival in patients with folliculotropic mycosis fungoides, according to a study published in JAMA Dermatology.

Melanoma development in skin of color may not be exacerbated by UV exposure, according to a study published in JAMA Dermatology.

The FDA cleared an investigational new drug application for LB1901, a chimeric antigen receptor T-cell therapy in development for treatment of adults with relapsed or refractory T-cell lymphoma, according to the agent’s manufacturer.

Local recurrence rates of male genital skin cancer were low for patients who underwent Mohs micrographic surgery, according to a study published in Journal of the American Academy of Dermatology.

The FDA approved drugs and products for many dermatological diseases and conditions in 2020. Here are some of the top-read articles on Healio regarding this year’s dermatology FDA approvals.

Actin expression may be the root of muscle spasms in patients with basal cell carcinoma who are treated with Hedgehog inhibitors, according to a study.

Recurrent basal cell carcinomas and primary basal cell carcinomas have a high likelihood of recurrence, according to a presentation at the European Academy of Dermatology and Venereology virtual congress.